Abstract
Methods: A total of 3,752 patients with stage IV disease from the prospective nationwide cohort database of the Japan Study Group of Prostate Cancer (J-CaP) were enrolled. All patients started primary androgen deprivation therapy (PADT) between 2001 and 2003, and the present study was performed using the data set from December 2011. Patients were divided into two groups according to initial treatments: CAB with luteinizing hormone-releasing hormone agonist (LHRH) plus anti-androgen (AA) and non-CAB treatments such as LHRH monotherapy. The overall survival (OS) and cancer-specific survival (CSS) for each group were estimated by the Kaplan–Meier method.
Purpose: To clarify which subset of stage IV prostate cancer patients benefit from combined androgen blockade (CAB) using Japanese nationwide database.
Results: A total of 2,967 patients (79.1 %) received CAB. Overall, no significant difference was observed in OS and CSS between the CAB group and the non-CAB group. However, CAB resulted in significantly better OS and CSS compared to non-CAB in patients with very high Japan Cancer of the Prostate Risk Assessment (J-CAPRA) scores of ten or greater (P = 0.007 and 0.013, respectively). Multivariate analysis revealed that CAB was an independent predictive factor for better OS (P = 0.013, hazard ratio = 0.83).
Conclusions: Based on large-scale nationwide database, as PADT for prostate cancer patients with very high-risk disease, CAB resulted in better OS than other endocrine treatments.
| Original language | English |
|---|---|
| Pages (from-to) | 759-765 |
| Number of pages | 7 |
| Journal | Journal of Cancer Research and Clinical Oncology |
| Volume | 141 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2015 |
Fingerprint
Keywords
- Combined androgen blockade
- Primary androgen deprivation therapy
- Prostate cancer
- Stage IV
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Medicine(all)
Cite this
Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer. / Matsuoka, Taeko; Kawai, Koji; Kimura, Tomokazu; Kojima, Takahiro; Onozawa, Mizuki; Miyazaki, Jun; Nishiyama, Hiroyuki; Hinotsu, Shiro; Akaza, Hideyuki.
In: Journal of Cancer Research and Clinical Oncology, Vol. 141, No. 4, 2015, p. 759-765.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer
AU - Matsuoka, Taeko
AU - Kawai, Koji
AU - Kimura, Tomokazu
AU - Kojima, Takahiro
AU - Onozawa, Mizuki
AU - Miyazaki, Jun
AU - Nishiyama, Hiroyuki
AU - Hinotsu, Shiro
AU - Akaza, Hideyuki
PY - 2015
Y1 - 2015
N2 - Methods: A total of 3,752 patients with stage IV disease from the prospective nationwide cohort database of the Japan Study Group of Prostate Cancer (J-CaP) were enrolled. All patients started primary androgen deprivation therapy (PADT) between 2001 and 2003, and the present study was performed using the data set from December 2011. Patients were divided into two groups according to initial treatments: CAB with luteinizing hormone-releasing hormone agonist (LHRH) plus anti-androgen (AA) and non-CAB treatments such as LHRH monotherapy. The overall survival (OS) and cancer-specific survival (CSS) for each group were estimated by the Kaplan–Meier method.Purpose: To clarify which subset of stage IV prostate cancer patients benefit from combined androgen blockade (CAB) using Japanese nationwide database.Results: A total of 2,967 patients (79.1 %) received CAB. Overall, no significant difference was observed in OS and CSS between the CAB group and the non-CAB group. However, CAB resulted in significantly better OS and CSS compared to non-CAB in patients with very high Japan Cancer of the Prostate Risk Assessment (J-CAPRA) scores of ten or greater (P = 0.007 and 0.013, respectively). Multivariate analysis revealed that CAB was an independent predictive factor for better OS (P = 0.013, hazard ratio = 0.83).Conclusions: Based on large-scale nationwide database, as PADT for prostate cancer patients with very high-risk disease, CAB resulted in better OS than other endocrine treatments.
AB - Methods: A total of 3,752 patients with stage IV disease from the prospective nationwide cohort database of the Japan Study Group of Prostate Cancer (J-CaP) were enrolled. All patients started primary androgen deprivation therapy (PADT) between 2001 and 2003, and the present study was performed using the data set from December 2011. Patients were divided into two groups according to initial treatments: CAB with luteinizing hormone-releasing hormone agonist (LHRH) plus anti-androgen (AA) and non-CAB treatments such as LHRH monotherapy. The overall survival (OS) and cancer-specific survival (CSS) for each group were estimated by the Kaplan–Meier method.Purpose: To clarify which subset of stage IV prostate cancer patients benefit from combined androgen blockade (CAB) using Japanese nationwide database.Results: A total of 2,967 patients (79.1 %) received CAB. Overall, no significant difference was observed in OS and CSS between the CAB group and the non-CAB group. However, CAB resulted in significantly better OS and CSS compared to non-CAB in patients with very high Japan Cancer of the Prostate Risk Assessment (J-CAPRA) scores of ten or greater (P = 0.007 and 0.013, respectively). Multivariate analysis revealed that CAB was an independent predictive factor for better OS (P = 0.013, hazard ratio = 0.83).Conclusions: Based on large-scale nationwide database, as PADT for prostate cancer patients with very high-risk disease, CAB resulted in better OS than other endocrine treatments.
KW - Combined androgen blockade
KW - Primary androgen deprivation therapy
KW - Prostate cancer
KW - Stage IV
UR - http://www.scopus.com/inward/record.url?scp=84925463203&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925463203&partnerID=8YFLogxK
U2 - 10.1007/s00432-014-1856-3
DO - 10.1007/s00432-014-1856-3
M3 - Article
C2 - 25326347
AN - SCOPUS:84925463203
VL - 141
SP - 759
EP - 765
JO - Journal of Cancer Research and Clinical Oncology
JF - Journal of Cancer Research and Clinical Oncology
SN - 0171-5216
IS - 4
ER -